No Prescription: Palatin Technologies, Inc. Announces Dosing Of Subcutaneous Bremelanotide Trial In Men

Palatin Technologies, Inc. Announces Dosing Of Subcutaneous Bremelanotide Trial In Men
Palatin Technologies, Inc. (NYSE Amex: PTN) announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old...
Source: mnt.to

Minimally Invasive Radical Prostatectomy Shows Some Advantages, But Also Higher Rate Of Certain Complications
New research indicates that the use of minimally invasive procedures (including the use of robotic assistance) for radical prostatectomy, which have increased significantly in recent years, may shorten hospital stays and decrease respiratory and surgical complications, but may also result in an increased rate of certain complications, including incontinence and erectile dysfunc...
Source: mnt.to

PharMEDium Participates In Anesthesia Patient Safety Foundation Summit: Medication Safety In The Operating Room; Time For A New Paradigm
PharMEDium Services, LLC, announced their participation in the Anesthesia Patient Safety Foundation (APSF) Summit held January 26th in Phoenix, AZ. PharMEDium's commitment to patient safety aligned with the APSF goals of improving medication safety by offering a complete line of pre-filled, pre-labeled Anesthesia syringe medications intended for use in the Operating Room...
Source: mnt.to

News From The February Issue Of Chest
BENEFITS OF ICS FOR COPD MAY BE OVERSTATED Inhaled corticosteroids (ICS) are widely used for the treatment of chronic obstructive pulmonary disease (COPD). However, new research suggests that ICS may only provide a modest benefit in reducing exacerbations in patients with COPD...
Source: mnt.to

Growing Animal Penile Erectile Tissue In Lab May Benefit Patients
In an advance that could one day enable surgeons to reconstruct and restore function to damaged or diseased penile tissue in humans, researchers at Wake Forest University Baptist Medical Center's Institute for Regenerative Medicine have used tissue engineering techniques to completely replace penile erectile tissue in animals. In the online early edition (Nov...
Source: mnt.to

Rexahn Pharmaceuticals Submits Zoraxel Phase IIb Protocol To FDA
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, announced that it has submitted a Phase IIb protocol to the FDA for ZoraxelTM for the treatment of erectile dysfunction (ED). "The progression of Zoraxel's clinical program is very encouraging," said Rexahn Chief Executive Officer, Dr...
Source: mnt.to

Drug Shows Promise In Treating Dangerous Complication Of Erectile Disorder
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections. There are limited treatment options, but a solution could be on the way thanks to new research at The University of Texas Health Science Center at Houston. Priapism is a condition of persistent painful penile erection in the absence of sexual desire...
Source: mnt.to

Better Control Of Drug Use Can Save 400 Swedish Lives Per Year
A scientific study indicates that the lives of 400 Swedes could be saved annually if measures were taken to prevent side effects of pharmaceuticals...
Source: mnt.to

Pivotal Study For PSD502--The First Potential Treatment For Premature Ejaculation
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE)...
Source: mnt.to

# posted by Network @ 10:39 PM